Immune checkpoint inhibitors (ICIs), including antibodies against the programmed cell death protein 1/ligand 1 (PD-1/L1) ...

EOM Pharmaceutical Holdings, Inc. (OTC: IMUC) ("EOM") an innovative biotechnology company focused on developing transformative treatments for chronic inflammatory conditions and debilitating retinal ...

Sept. 14 (UPI) --A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical tests, drugmaker Pfizer announced Saturday. The experimental ...

Cachexia is a paraneoplastic syndrome of unintentional adipose and muscle tissue wasting with severe impacts to functionality and quality of life. Although health inequities across minority and ...

Cancer is insidious. Throughout tumor progression, the disease hijacks otherwise healthy biological processes - like the body's immune response - to grow and spread. When tumors elevate levels of an ...

When new data for anamorelin were presented at a large European meeting in 2014, oncology experts enthusiastically welcomed them, and hopes were raised that there may at last be a drug for cancer ...

Ponsegromab increased weight and activity levels in cachexia patients, confirming GDF-15 as a key driver and therapeutic target. Significant weight gain was observed in ponsegromab-treated groups ...

The investigational drug ponsegromab — which inhibits growth differentiation factor 15 (GDF-15), a cytokine elevated in cancer cachexia — increases weight, appetite, and physical activity in patients ...

Our bodies begin their physical decline earlier than is generally believed, but it remains possible to favorably influence this trajectory. A Swedish investigation spanning nearly half a ...